WaVe Life Sciences

Edit info

Founded: 2012

Location: Cambridge, MA

Employee range: 200 - 500

Clinical stage: Clin1b/Clin2a

Therapy area: ALS, FTD (partner: Takeda)

Drug types: NEU, GEN, MUS, LNG, HEP

Lead product: WVE-004

Funding: $70M stock Jun 2022; $100M stock Sep 2020

wavelifesciences.com

linkedin.com

job board

Drug notes:

WVE-003 Clin1/Clin2 Huntington's disease (partner: Takeda); WVE-N531 Clin1/Clin2 DMD; WVE-006 Clin0 AATD - lung & liver disease; 3 undisclosed programs Clin0 spinocerebellar ataxia 3, CNS diseases

About:

Wave Life Sciences is developing novel oligonucleotide therapies for the treatment of rare genetic diseases. The company's PRISM platform enables the precise design, optimization, and production of stereopure oligonucleotides. Unlike traditional oligonucleotides, which are racemic mixtures of stereoisomers, stereopure oligonucleotides are composed of only one stereoisomer. This makes stereopure oligonucleotides more potent and less toxic than traditional oligonucleotides. Wave Life Sciences is using its PRISM platform to develop stereopure oligonucleotide therapies for a variety of rare genetic diseases, including Huntington's disease, Duchenne muscular dystrophy, and Batten disease. The company's lead product candidate, WVE-001, is a stereopure oligonucleotide therapy for the treatment of Huntington's disease.